Loading…
← CockpitCompetitor Analysis › PRTC.L PureTech Health PLCOpen in the cockpit ↗

PureTech Health PLCPRTC.LCompetitor analysis, valuation and peers

United Kingdom · GBP·Health Care›Biotechnology
Momentum weak 36
Mkt cap
$378M
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$680,048
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-57.1 pp
WACC 12.2%
Hurdle
n/a
no reverse DCF
Next earnings
162 days
29 Apr 2027
Close · GBP£117.40
1D-0.5%
1W-6.8%
1M+3.2%
3M+0.5%
6M-14.7%
YTD-6.1%
1Y-1.3%
ATR %4.0%
52w lowhigh18.2% off high

What PureTech Health does

No business profile yet.

PureTech Health at a glance

Size PureTech Health (PRTC.L) is a United Kingdom Health Care company (Biotechnology) with a market value of $378M, the 324th largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £117.40 on 18 Nov 2026.

Performance Over six months the shares fell 14.7%, against -31.1% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue fell 4.1% over the last twelve months (peer median +6.3%); the operating margin is -1,616.9% (peer median 5.0%).

Valuation It trades at 27.4× enterprise value to sales against a peer median of 3.9× (2nd most expensive of 16).

Capital Return on invested capital runs 57.1 points below its cost of capital (12.2% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026PRTC.L 84Peer median 70
Six months, rebased to 100: PureTech Health against the median of its 20 peers (local-currency closes).

PureTech Health financials

Reported figures in GBP; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue£4.74M£3.54M£3.78M£2.68M£12.7M
Revenue growth—-6%+41%-79%—
Gross profit£2.28M£994,772£983,713-£1.29Mn/a
EBITDA-£74.2M-£72.2M-£104M-£114M-£153M
Net income£1.35M-£83.3M£41.9M-£52.9M-£40.9M
Free cash flow-£61.2M-£64.6M-£105M-£85.3M-£147M
Capital expenditure£4,481£4,553£8,608£197,096£1.77M
Total debtn/a£14.7M£18.0M£20.0M£61.7M

Quarterly statements and history in the cockpit →

PureTech Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-25%0%+25%ALEC300966300381PNV476060688687CTNM300683CRMD688098116733786998688238EPRX688163456160PRTC.L6-month return →1-month return →
Up and to the right = strong over both horizons. PureTech Health is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×500×ALEC3009663003814760606998456160PRTC.LRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. PureTech Health is the large dot.

PureTech Health competitors and peer comparison

How PureTech Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PureTech Health against its 20 peers (data as of 18 Nov 2026)
MeasurePRTC.LPeer medianRank in peer set
1-month return+3.2%-9.2%3rd highest of 20
6-month return-14.7%-31.1%4th highest of 20
Distance from 52-week high-18.2%-47.2%2nd highest of 20
Revenue growth (TTM)-4.1%+6.3%4th lowest of 16
Operating margin-1,616.9%5.0%2nd lowest of 16
EV / Sales27.4×3.9×2nd most expensive of 16
ROIC minus cost of capital-57.1 pp-8.4 pp3rd lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
PureTech Health PRTC.LUnited Kingdom$378M-15%-4%-1,617%27.4×n/an/a
Alector ALECUnited States$383M+21%+151%25%1.5×n/an/a
Hubei Goto Biopharm 300966.SZChina$386M-16%+6%-10%6.0×n/an/a
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a
Polynovo PNV.AXAustralia$388M-34%+13%5%3.9×51.9%+37.6%
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Beijing Kawin Technology Share-Holding 688687.SSChina$391M-20%+6%-2%1.7×36.6%+8.9%
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%5.2×n/an/a
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/an/an/an/a
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%10.9×n/an/a
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%1.9×-18.8%-36.1%
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%1.0×-15.3%+197.3%
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%10.3×n/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%10.6×n/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%908.6×n/an/a

Questions

Which companies are PureTech Health's closest peers?
The cockpit's peer set: Alector (ALEC), Hubei Goto Biopharm (300966.SZ), Guangdong Vtr Bio-Tech (300381.SZ), Polynovo (PNV.AX), Onconic Therapeutics (476060.KS), Beijing Kawin Technology Share-Holding (688687.SS), Contineum Therapeutics (CTNM), Wuhan Hiteck Biological Pharma (300683.SZ).
Is PureTech Health expensive compared with its peers?
On ev / sales it trades at 27.4× against a peer median of 3.9×, 2nd most expensive of 16 in its peer set.
How has PureTech Health stock performed?
Over six months to 18 Nov 2026 the shares returned -14.7% against -31.1% for the median peer; over one year -1.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.